02859nam a22004215i 4500001001800000003000900018005001700027007001500044008004100059020003700100024003500137050001200172072001600184072002300200072001500223100008600238245008300324250001800407264006900425300003200494336002600526337002600552338003600578347002400614505056700638520092101205650002602126650002602152710003402178773002602212776003602238776003602274776003602310856004602346912001402392912001402406999001702420978-3-031-58811-2DE-He21320251030112608.0cr nn 008mamaa240702s2024    sz |    s    |||| 0|eng d  a97830315881129978-3-031-58811-27 a10.1007/978-3-031-58811-22doi 4aRE1-994 7aMJQ2bicssc 7aMED0630002bisacsh 7aMJQ2thema1 aWeiss, Jeffrey N.eauthor.4aut4http://id.loc.gov/vocabulary/relators/aut97986210aAlzheimer's Disease and the Eyeh[electronic resource] /cby Jeffrey N. Weiss.  a1st ed. 2024. 1aCham :bSpringer Nature Switzerland :bImprint: Springer,c2024.  aX, 139 p.bonline resource.  atextbtxt2rdacontent  acomputerbc2rdamedia  aonline resourcebcr2rdacarrier  atext filebPDF2rda0 aPart 1: Introduction -- Chapter 1. Alzheimer's Disease -- Chapter 2. Rates of Dementia -- Chapter 3. Biomarkers and Clinical Endpoints -- Chapter 4. Ocular Biomarkers -- Part 2: Diagnosis -- Chapter 5. Biochemical and Neuroimaging -- Chapter 6. Cognitive Decline -- Chapter 7. EEG/ERP -- Chapter 8. Eye Tracking -- Chapter 9. Light Intervention -- Chapter 10. Retina -- Chapter 11. Tears -- Chapter 12. Telemedicine -- Chapter 13. Virtual Reality -- Part 3: Treatment -- Chapter 14. Recruiting Trials in the US -- Chapter 15. Not Yet Recruiting Trials in the US.  aThis book is a compendium of the worldwide studies of Alzheimer’s disease utilizing the eye as a biomarker, or as a treatment method, that are registered with the United States National Institutes of Health website, clinicaltrials.gov. Clinicaltrials.gov is the largest listing of research studies in the world. The study titles are provided, as is the country of origin and the Clinical Trial Number in order to make it easier for the reader to locate the study and obtain further information. New drug development is costly and time consuming. If through the use of biomarkers, study durations and research costs decrease, there is a greater possibility of a new and effective drug to treat this devastating disease. The eye offers the possibility of early diagnosis and of treatment. Alzheimer’s Disease and the Eye is a valuable resource for ophthalmologists, optometrists, other physicians, and researchers. 0aOphthalmology.97207214aOphthalmology.9720722 aSpringerLink (Online service)0 tSpringer Nature eBook08iPrinted edition:z978303158810508iPrinted edition:z978303158812908iPrinted edition:z978303158813640uhttps://doi.org/10.1007/978-3-031-58811-2  aZDB-2-SME  aZDB-2-SXM  c61258d61258